NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/04/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,549.77 mln
Float47.51 mln
Earnings Date11/17/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
33.50
Exceptional upside
Relative Strength
25
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-41.71
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Bicara Therapeutics Inc. is a Boston-based medical research company focused on developing new treatments for solid tumor cancers. Founded in 2018, the company is advancing ficerafusp alfa, its primary drug candidate, which works by targeting two key biological pathways involved in tumor growth at the same time. This dual-action approach is designed to improve on existing cancer therapies and offer better outcomes for patients.
